Bardoxolone methyl: drug development for diabetic kidney disease
Open Access
- 27 June 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical and Experimental Nephrology
- Vol. 24 (10), 857-864
- https://doi.org/10.1007/s10157-020-01917-5
Abstract
Bardoxolone methyl activates the Keap1/Nrf2 system that plays an important role in defense responses against oxidative stress. Importantly, bardoxolone methyl has demonstrated increases in estimated glomerular filtration rate (eGFR) in patients with diabetic kidney disease (DKD) in clinical studies. However, an overseas Phase 3 study of bardoxolone methyl in patients with stage G4 DKD was prematurely terminated due to an increased risk for heart failure, which was considered to have been caused by early-onset fluid overload. Subsequently, a Japanese Phase 2 study demonstrated, for the first time, that bardoxolone methyl directly improves GFR, which is a true indicator of kidney function, using the inulin clearance method. In Japan, bardoxolone methyl was designated for the treatment of DKD under the Priority Review and Designation (SAKIGAKE Designation) System established by the Ministry of Health, Labour and Welfare. A Japanese Phase 3 study, with endpoints such as a ≥ 30% decrease in eGFR, is currently ongoing to assess the efficacy and safety of bardoxolone methyl in more than 1,000 patients with stages G3 and G4 DKD who have no identified risk factors.Keywords
Funding Information
- Kyowa Kirin Co.,Ltd.
This publication has 35 references indexed in Scilit:
- The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox HomeostasisPhysiological Reviews, 2018
- 2017 Annual Dialysis Data Report, JSDT Renal Data RegistryNihon Toseki Igakkai Zasshi, 2018
- Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney DiseaseThe New England Journal of Medicine, 2017
- Recent advances in understanding of chronic kidney diseaseF1000Research, 2015
- Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKDJournal of the American Society of Nephrology, 2015
- Synthetic Oleanane Triterpenoids: Multifunctional Drugs with a Broad Range of Applications for Prevention and Treatment of Chronic DiseasePharmacological Reviews, 2012
- An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal functionKidney International, 2011
- Effect of a Carbonaceous Oral Adsorbent on the Progression of CKD: A Multicenter, Randomized, Controlled TrialAmerican Journal of Kidney Diseases, 2009
- Effects of high-dose vitamin E supplementation on oxidative stress and microalbuminuria in young adult patients with childhood onset type 1 diabetes mellitusDiabetes/Metabolism Research and Reviews, 2007
- Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region.Proceedings of the National Academy of Sciences of the United States of America, 1994